Heaves hit for Stirling
Tuesday, 29 July, 2008
Stirling Products [ASX: STI] has been granted an Australian patent or the treatment of heaves in horses with R-salbutamol.
The company has already been granted a patent for the same concept from South Africa, and Stirling representatives say they expect more grants to follow shortly.
A patent application for the inhaler device developed to help administer the drug, the Equinehaler, has also been lodged.
Heaves, also known as recurrent airway obstruction, affects an estimated 25-30 per cent of all horses in Europe and the US.
Stirling is also looking at using R-salbutamol - a highly purified version of salbutamol, better known as Ventolin - as a growth agent and as a treatment of obesity in dogs.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
